# Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma

> **NCT05498545** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Second Affiliated Hospital of Xi'an Jiaotong University** · enrollment: 34 (estimated)

## Conditions studied

- Relapsed/Refractory Multiple Myeloma

## Interventions

- **BIOLOGICAL:** LUCAR-B68 cells product

## Key facts

- **NCT ID:** NCT05498545
- **Lead sponsor:** Second Affiliated Hospital of Xi'an Jiaotong University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2022-09
- **Primary completion:** 2024-12
- **Final completion:** 2027-03
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2022-08-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05498545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05498545, "Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05498545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*